EQUITY RESEARCH MEMO
Nuo Therapeutics
Generated 5/10/2026
Executive Summary
Conviction (model self-assessment)55/100
Nuo Therapeutics is a commercial-stage medical device company in the regenerative medicine space, focused on advanced wound care. Its lead product, Aurix, is a biodynamic hematogel made from the patient's own platelets and plasma, designed to stimulate natural healing. The company emphasizes individualized, biologically relevant therapies for chronic and acute wounds. As a private firm, it continues to expand its commercial footprint and explore new indications.
Upcoming Catalysts (preview)
- Q4 2026FDA 510(k) clearance for expanded indication of Aurix in diabetic foot ulcers70% success
- Q3 2026Strategic distribution partnership with a major hospital network60% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)